ADC Therapeutics secures cash runway to 2028 amid pivotal clinical momentum
ADC Therapeutics (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation antibody-drug conjugates (ADCs), reported a steady fourth quarter for 2025 and a significantly strengthened balance sheet on Tuesday.











